Ravi A. Madan, M.D.
Dr. Madan is the clinical director of the Genitourinary Malignancies Branch. His clinical research is focused on immune stimulating therapies and prostate cancer. Specifically, Dr. Madan’s clinical trials are designed to develop a better understanding of how immune stimulating therapies can improve clinical outcomes and be combined with other therapies. In addition to investigating emerging therapeutics in all stages of prostate cancer, Dr. Madan is exploring immunotherapy treatment strategies in rare tumors such as medullary thyroid cancer.
1) immunotherapy, 2) prostate cancer, 3) therapeutic cancer vaccines, 4) immune check point inhibitors, 5) metastatic prostate cancer, 6) medullary thyroid cancer
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.Lancet Oncol.. 13: 501-8, 2012. [ Journal Article ]
Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.Cancer Immunol. Immunother.. 63: 225-34, 2014. [ Journal Article ]
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.Cancer Immunol. Immunother.. 59: 663-74, 2010. [ Journal Article ]
Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression.Oncologist. 15: 969-75, 2010. [ Journal Article ]
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy.Clin. Cancer Res.. 14: 4526-31, 2008. [ Journal Article ]
Dr. Madan is an Assistant Clinical Investigator at the National Cancer Institute (NCI), conducting clinical research in therapeutic cancer vaccines and genitourinary malignancies. Dr. Madan received his M.D. from the UMDNJ-New Jersey Medical School in 2001 and completed his internal medicine residency at UMDNJ-University Hospital in June 2004. He joined the NCI Medical Oncology Branch as an oncology/hematology fellow in 2005. He currently holds a joint appointment in the Medical Oncology Branch and the Laboratory of Tumor Immunology and Biology. His research interests are focused on immune stimulating therapeutic cancer vaccines and novel therapies in the treatment of prostate cancer.
|Philip Arlen M.D.||Special Volunteer|
|Guinevere Chun||Research Nurse|
|Carlos Diaz||Patient Care Coordinator (Contr.)|
|Amy Hankin PA-C, MMSc||Physician Assistant|
|Elizabeth Lamping R.N., B.S.N.||Research Nurse|
|Sheri McMahon R.N., B.S.N.||Research Nurse|
|Michelle Ojemuyiwa M.D.||Clinical Collaborator|
|Helen Owens||Research Nurse|
|Lee Pai-Scherf M.D.||Clinical Collaborator|
|Myrna Rauckhorst R.N.||Research Nurse|
|Moniquea Smith||Patient Care Coordinator (Contr.)|
|Marc Theoret M.D.||Clinical Collaborator|
|Monique Williams N.P.||Nurse Practitioner (Contr.)|